Chest
Original ResearchPulmonary Vascular DiseaseOral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study): A Randomized Controlled Trial
Section snippets
Patient Population
Eligible patients were aged 18 to 75 years with idiopathic PAH (IPAH) (including PAH associated with appetite suppressant or toxin use), familial PAH (FPAH), or PAH associated with congenital heart disease (repaired congenital systemic-to-pulmonary shunts for ≥ 5 years); connective tissue disease; or HIV. Diagnosis of PAH required a mean pulmonary arterial pressure of > 25 mm Hg, pulmonary capillary wedge pressure or left ventricular end-diastolic pressure of ≤ 15 mm Hg, pulmonary vascular
Patient Demographics and Disposition
A total of 310 patients (oral treprostinil, 157; placebo, 153) were randomized and received the study drug between June 15, 2009, and July 22, 2011 (Fig 1). The mean age for the study population was 51 years (range, 18-76 years). Patients were primarily women (78%) with IPAH or FPAH (65%) and World Health Organization functional class III (73%) symptoms (Table 1). At baseline, 53 patients (17%) were receiving ERA therapy alone, 132 (43%) were receiving PDE-5I therapy alone, and 125 (40%) were
Discussion
Sixteen weeks of oral treprostinil in combination with stable background therapy of ERA, PDE-5I, or both failed to improve exercise capacity in patients with PAH. There were no significant improvements in secondary end points. Although adverse events were common with oral treprostinil, it was well tolerated by most patients; the most frequent side effects were consistent with prostacyclin therapy.
For the primary end point, the change in 6MWD from baseline to week 16 was 10 m; this was not
Conclusions
Sixteen weeks of oral treprostinil therapy did not significantly improve 6MWD in patients with PAH receiving background therapy of ERA, PDE-5I, or both. Oral treprostinil therapy in combination with ERA and PDE-5I therapy appeared to be safe. Although side effects were common, they were tolerated by most patients. Additional studies of longer duration would be required to fully evaluate the clinical benefit of oral treprostinil therapy at higher doses in combination with ERA or PDE-5I
Acknowledgments
Author contributions: Dr Tapson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Tapson: contributed to the study design; data collection, analysis, and interpretation; and drafting, critical review, and final approval of the manuscript.
Dr Jing: contributed to the data collection, analysis, and interpretation and critical review and final approval of the manuscript.
Dr Xu: contributed to the data
References (19)
- et al.
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J Am Coll Cardiol
(2009) - et al.
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist
Biochem Pharmacol
(2012) - et al.
Cellular and molecular pathobiology of pulmonary arterial hypertension
J Am Coll Cardiol
(2004) - et al.
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial
J Heart Lung Transplant
(2010) - et al.
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
J Am Coll Cardiol
(2010) - et al.
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial
Chest
(2012) - et al.
Treatment of pulmonary arterial hypertension
N Engl J Med
(2004) - et al.
Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery
Am J Respir Cell Mol Biol
(2002) - et al.
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
Am J Respir Crit Care Med
(2002)
Cited by (266)
Perioperative Management of Novel Pharmacotherapies for Heart Failure and Pulmonary Hypertension
2024, Anesthesiology ClinicsParenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil
2023, Respiratory MedicinePulmonary arterial hypertension
2023, Presse MedicaleRecent Advances in Pediatric Pulmonary Hypertension: Implications for Diagnosis and Treatment
2023, Clinical TherapeuticsEfficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials
2022, Pulmonary Pharmacology and Therapeutics
Funding/Support: This research was funded by United Therapeutics Corporation.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.